TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Neurotech International ( (AU:NTI) ).
Neurotech International has appointed Dr. Bonni Goldstein as Chief Medical Advisor USA, enhancing its strategic capabilities in cannabinoid-based therapies for paediatric neurological disorders. Dr. Goldstein’s extensive experience and network are expected to bolster Neurotech’s regulatory strategy and clinical advancement in the US, particularly as the company progresses NTI164 towards commercialisation. Her appointment is seen as a strong validation of Neurotech’s innovative approach and the potential of NTI164 in treating neurological conditions, increasing the company’s visibility and impact in the US market.
More about Neurotech International
Neurotech International Limited is a clinical-stage biopharmaceutical company focused on developing therapies for paediatric neurological disorders. The company is advancing a broad-spectrum oral cannabinoid drug therapy called NTI164, which has shown promising results in clinical trials for conditions such as Autism Spectrum Disorder, PANDAS/PANS, and Rett Syndrome.
Average Trading Volume: 748,568
Technical Sentiment Signal: Sell
Current Market Cap: A$17.84M
See more insights into NTI stock on TipRanks’ Stock Analysis page.